LKT Labs

Biochemicals for Life Science Research

Dabrafenib Mesylate

Dabrafenib Mesylate

Product ID D0005
Cas No. 1195768-06-9
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $68.30 In stock
25 mg $152.30 In stock
100 mg $362.30 In stock
Bulk Quote

Quicklinks

Description

Dabrafenib is a reversible kinase inhibitor with anticancer chemotherapeutic activity. This compound is selective primarily for mutant (V600E) B-Raf, but has also inhibited tumor growth in cells expressing other B-Raf mutants (V600K, V600D) and WT B-Raf. Dabrafenib is partially active against c-Raf as well. Dabrafenib is an ATP-competitive inhibitor that has been approved for clinical use in the treatment of unresectable or metastatic melanomas; it is also being examined for treatment of brain metastases and other cancers. This compound has a very high oral bioavailability.

Product Info

Cas No.

1195768-06-9
Purity

≥98%
Formula

C23H20F3N5O2S2・CH3SO3H
Formula Wt.

615.67
Chemical Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2, 6-difluorobenzenesulfonamide;methanesulfonic acid
IUPAC Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2, 6-difluorobenzenesulfonamide;methanesulfonic acid
Solubility

soluble in DMSO
Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

D0005 MSDS PDF
Info Sheet

D0005 Info Sheet PDF
Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • A7460

    Asparaginase

    Catalyzes hydrolysis of asparagine.

    ≥98%
  • C0044

    CAL101

    p110δ PI3K inhibitor.

    ≥99%
  • O4917

    Omeprazole

    H+/K+ ATPase inhibitor.

    ≥98%
  • E543721

    Ensartinib

    A third-generation ALK inhibitor.

    ≥98%
  • B5753

    Bongkrekic Acid

    Respiratory toxin, mitochondrial permeability t...

    ≥95%
  • S0344

    Salermide

    SIRT inhibitor.

    ≥98%
  • A5228

    Angiogenin

    Small protein, cleaves RNA.

    ≥98%
  • I7659

    1-Isothiocyanato-8-(methylsulfonyl)-octane

    ITC, erysolin analog.

    ≥98%
  • T0115

    Taxol Side Chain Acid

    Side chain commonly attached to taxanes.

    ≥98%
  • I1257

    Idoxuridine

    Nucleoside (deoxyuridine) analog; DNA chain ter...

    ≥98%
  • P3441

    PIK-294

    p110δ PI3K inhibitor.

    ≥98%
  • D1769

    Dermorphin

    Opioid peptide; μOR agonist.

    ≥96%
  • L8278

    Luteinizing Hormone Releasing Hormone, salmon

    Endogenous peptide hormone, involved in secreti...

    ≥95%
  • E7857

    Etofenamate

    NSAID; COX-1/2 and lipoxygenase inhibitor.

    ≥98%
  • S0278

    Satraplatin

    Pt-based DNA cross-linker.

    ≥98%
  • G1849

    Gemifloxacin Mesylate

    Fluoroquinolone; bacterial DNA gyrase inhibitor...

    ≥99%
  • M4652

    MLN8237

    AurKA inhibitor.

    ≥98%
  • D3262

    Dipropyl Sulfide

    Organosulfide found in Allium; cholesterol synt...

    ≥99%
  • L9602

    LY-2874455

    FGFR inhibitor.

    ≥98%
  • T1025

    D-Seco Paclitaxel

    D-Seco Paclitaxel is an impurity in the product...

    ≥90%